Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
Caspar Franck, Christian D. Muller, Rosa Rosania, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1955-1955
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Targeting hedgehog signaling in pancreatic ductal adenocarcinoma
Delphine Quatannens, Yannick Verhoeven, Peter A. van Dam, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108107-108107
Closed Access | Times Cited: 30
Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives
Eileen Tabrizi, Fatemeh Pourteymour Fard Tabrizi, Gehad Mahmoud Khaled, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery
Dina Mikdadi, Kyle A. O’Connell, Philip J. Meacham, et al.
Cancer Biomarkers (2022) Vol. 33, Iss. 2, pp. 173-184
Open Access | Times Cited: 24
Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA
Xiao Xu, Xiang Wang, Yu‐Pei Liao, et al.
ACS Nano (2025)
Closed Access
Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates
Laura De Lellis, Serena Veschi, Nicola Tinari, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 3946-3946
Open Access | Times Cited: 28
Artificial intelligence in pancreatic cancer: diagnosis, limitations, and the future prospects—a narrative review
Maanya Rajasree Katta, Pavan Kumar Reddy Kalluru, Divyaraj Amber Bavishi, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6743-6751
Closed Access | Times Cited: 11
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
Ryoji Takada, Kenji Ikezawa, Kazuma Daiku, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4733-4733
Open Access | Times Cited: 19
Dissection of pyroptosis-related prognostic signature and CASP6-mediated regulation in pancreatic adenocarcinoma: new sights to clinical decision-making
Jun Zhu, Yanlong Shi, Sheng Lan, et al.
APOPTOSIS (2023) Vol. 28, Iss. 5-6, pp. 769-782
Open Access | Times Cited: 7
ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer
Ruizhe He, Jia-Hao Zheng, Hong-Fei Yao, et al.
Hepatobiliary & pancreatic diseases international (2022) Vol. 22, Iss. 2, pp. 169-178
Closed Access | Times Cited: 11
Early diagnosis of pancreatic cancer by machine learning methods using urine biomarker combinations
İREM ACER, Firat ORHAN BULUCU, SEMRA İÇER, et al.
TURKISH JOURNAL OF ELECTRICAL ENGINEERING & COMPUTER SCIENCES (2023) Vol. 31, Iss. 1, pp. 112-125
Open Access | Times Cited: 6
Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only
L. Brada, Lois A. Daamen, L. Magermans, et al.
Annals of Surgery (2021) Vol. 274, Iss. 5, pp. 729-735
Open Access | Times Cited: 15
Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy
Mirang Lee, Jae Seung Kang, Hongbeom Kim, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2021) Vol. 30, Iss. 1, pp. 111-121
Open Access | Times Cited: 14
Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
Kenji Ikezawa, Ryosuke Kiyota, Ryoji Takada, et al.
JGH Open (2021) Vol. 5, Iss. 6, pp. 679-685
Open Access | Times Cited: 13
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice
Hajime Kurosaki, Motomu Nakatake, Teruhisa Sakamoto, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 985-985
Open Access | Times Cited: 12
Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer
Kenji Ikezawa, Tomoya Ekawa, Shinichiro Hasegawa, et al.
Endoscopy International Open (2022) Vol. 10, Iss. 01, pp. E82-E87
Open Access | Times Cited: 8
Adipose Tissue Wasting as a Determinant of Pancreatic Cancer-Related Cachexia
Seok‐Yeong Yu, Yi Luan, Rosemary Dong, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4754-4754
Open Access | Times Cited: 8
RETRACTED ARTICLE: Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment
Fengyong Wang, Zhen Zhang
Pharmaceutical Research (2020) Vol. 37, Iss. 12
Closed Access | Times Cited: 12
Identifying the Morphological and Molecular Features of a Cell-Based Orthotopic Pancreatic Cancer Mouse Model during Growth over Time
Felista L. Tansi, Andrea Schrepper, Michael Schwarzer, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5619-5619
Open Access | Times Cited: 1
OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway
Yifan Yin, Qin-Yuan Jia, Hong-Fei Yao, et al.
Gene (2024) Vol. 927, pp. 148735-148735
Closed Access | Times Cited: 1
CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma
Chaoting Zhou, Luyang Wang, Wanye Hu, et al.
Bioengineered (2022) Vol. 13, Iss. 5, pp. 13089-13107
Open Access | Times Cited: 7
Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study
Kazuma Daiku, Kenji Ikezawa, Toshitaka Morishima, et al.
Journal of Geriatric Oncology (2022) Vol. 13, Iss. 8, pp. 1208-1215
Closed Access | Times Cited: 6
Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center
Lei Ren, Carsten Jäger, Stephan Schorn, et al.
Annals of Surgery Open (2023) Vol. 4, Iss. 3, pp. e302-e302
Open Access | Times Cited: 3
Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
Sofia Parrasia, Mario Zoratti, Ildikò Szabó, et al.
Cellular Physiology and Biochemistry (2020) Vol. 55, Iss. 1, pp. 61-90
Open Access | Times Cited: 8
BRCA mutations in pancreatic cancer and progress in their targeting
Samer Alkassis, Omid Yazdanpanah, Philip Agop Philip
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 7, pp. 547-557
Closed Access | Times Cited: 7
Identifying drug candidates for pancreatic ductal adenocarcinoma based on integrative multiomics analysis
Penglei Ge, Zhengfeng Wang, Jing Wang, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 3, pp. 1265-1281
Open Access
Page 1 - Next Page

Scroll to top